Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Samalizumab |
Synonyms | |
Therapy Description |
Samalizumab (ALXN6000) is a humanized antibody against CD200 which blocks CD200-CD200R interaction, resulting in enhanced immune response (Blood 2010 116:2465, PMID: 31443741). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Samalizumab | ALXN6000 | Samalizumab (ALXN6000) is a humanized antibody against CD200 which blocks CD200-CD200R interaction, resulting in enhanced immune response (Blood 2010 116:2465, PMID: 31443741). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02987504 | Phase I | Samalizumab | Study of Samalizumab in Patients With Advanced Cancer | Terminated | USA | 0 |